Literature DB >> 16344951

[Pharmacotherapy of supraventricular arrhythmias. What comes, what remains, what goes?].

T Lewalter1, G Nickenig.   

Abstract

Supraventricular tachycardias consist of AV-nodal-reentrant-tachycardias, atrioventricular tachycardias with accessory pathways (WPW-syndrome), atrial tachycardias, atrial fibrillation and atrial flutter. Only specific ECG interpretation with an exact arrhythmia classification offers the way to perform modern differential therapy including drug treatment and also interventional therapy modalities. In atrial fibrillation, drug treatment is still first-line therapy: physicians have to make a decision either to follow the rate or rhythm control concept. In case of rhythm control, drug therapy is tailored to the individual patient taking into account the patients symptomatology, left ventricular ejection fraction and nature and degree of an underlying cardiac disease. Drug refractory symptomatic atrial fibrillation patients should be considered for interventional treatment like pulmonary vein ablation. Recurrent typical right atrial flutter, AV-nodal-reentrant-tachycardia and all forms of atrioventricular tachycardias however are indications for catheter ablation; long-term drug treatment will only be performed in rare cases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16344951     DOI: 10.1007/s00108-005-1544-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  22 in total

1.  Prevalence, characteristics and natural course of inappropriate sinus tachycardia.

Authors:  Aino-Maija Still; Pekka Raatikainen; Antti Ylitalo; Heikki Kauma; Markku Ikäheimo; Y Antero Kesäniemi; Heikki V Huikuri
Journal:  Europace       Date:  2005-03       Impact factor: 5.214

Review 2.  How to manage patients with inappropriate sinus tachycardia.

Authors:  Win K Shen
Journal:  Heart Rhythm       Date:  2005-09       Impact factor: 6.343

Review 3.  [Recommendations for preclinical emergency medicine. Acute therapy of tachycardic cardiac arrhythmias].

Authors:  W Jung; B Lüderitz
Journal:  Internist (Berl)       Date:  1998-02       Impact factor: 0.743

Review 4.  Atrial tachycardia: mechanisms, diagnosis, and management.

Authors:  Kurt C Roberts-Thomson; Peter M Kistler; Jonathan M Kalman
Journal:  Curr Probl Cardiol       Date:  2005-10       Impact factor: 5.200

Review 5.  Clinical safety profile of sotalol in patients with arrhythmias.

Authors:  L F Soyka; C Wirtz; R B Spangenberg
Journal:  Am J Cardiol       Date:  1990-01-02       Impact factor: 2.778

6.  Amiodarone versus sotalol for atrial fibrillation.

Authors:  Bramah N Singh; Steven N Singh; Domenic J Reda; X Charlene Tang; Becky Lopez; Crystal L Harris; Ross D Fletcher; Satish C Sharma; J Edwin Atwood; Alan K Jacobson; H Daniel Lewis; Dennis W Raisch; Michael D Ezekowitz
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

7.  Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation.

Authors:  C Ozcan; A Jahangir; P A Friedman; P J Patel; T M Munger; R F Rea; M A Lloyd; D L Packer; D O Hodge; B J Gersh; S C Hammill; W K Shen
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

8.  Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach.

Authors:  Paolo Alboni; Giovanni L Botto; Nicola Baldi; Mario Luzi; Vitantonio Russo; Lorella Gianfranchi; Paola Marchi; Massimo Calzolari; Alberto Solano; Raffaele Baroffio; Germano Gaggioli
Journal:  N Engl J Med       Date:  2004-12-02       Impact factor: 91.245

Review 9.  Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.

Authors:  Dario DiFrancesco; John A Camm
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group.

Authors:  G V Naccarelli; P Dorian; S H Hohnloser; P Coumel
Journal:  Am J Cardiol       Date:  1996-01-25       Impact factor: 2.778

View more
  1 in total

Review 1.  [Electrical and pharmacological strategies for early cardioversion of atrial fibrillation].

Authors:  M Linhart; T Lewalter
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.